These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28580308)

  • 1. A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines.
    Haghiralsadat F; Amoabediny G; Sheikhha MH; Forouzanfar T; Helder MN; Zandieh-Doulabi B
    Cell J; 2017; 19(Suppl 1):55-65. PubMed ID: 28580308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
    Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to the development and assessment of doxorubicin-loaded nanoliposomes for the treatment of osteosarcoma in 2D and 3D cell culture systems.
    Parchami M; Haghiralsadat F; Sadeghian-Nodoushan F; Hemati M; Shahmohammadi S; Ghasemi N; Sargazi G
    Heliyon; 2023 May; 9(5):e15495. PubMed ID: 37153425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gold nanoconjugates reinforce the potency of conjugated cisplatin and doxorubicin.
    Iram S; Zahera M; Khan S; Khan I; Syed A; Ansary AA; Ameen F; Shair OHM; Khan MS
    Colloids Surf B Biointerfaces; 2017 Dec; 160():254-264. PubMed ID: 28942160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
    Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
    Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity.
    Haghiralsadat F; Amoabediny G; Sheikhha MH; Zandieh-Doulabi B; Naderinezhad S; Helder MN; Forouzanfar T
    Chem Biol Drug Des; 2017 Sep; 90(3):368-379. PubMed ID: 28120466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
    Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
    ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy.
    Yu J; Wang Y; Zhou S; Li J; Wang J; Chi D; Wang X; Lin G; He Z; Wang Y
    Acta Pharm Sin B; 2020 Sep; 10(9):1730-1740. PubMed ID: 33088692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
    Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
    Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
    Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
    Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations.
    Du H; Cui C; Wang L; Liu H; Cui G
    Mol Pharm; 2011 Aug; 8(4):1224-32. PubMed ID: 21630705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells.
    Wang J; Goh B; Lu W; Zhang Q; Chang A; Liu XY; Tan TM; Lee H
    Biol Pharm Bull; 2005 May; 28(5):822-8. PubMed ID: 15863886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
    Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
    Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
    Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
    Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preparation and evaluation of doxorubicin hydrochloride liposomes modified by poly(2-ethyl-2-oxazoline)-cholesteryl methyl carbonate].
    Zhang D; Li JY; Wang XC; Yue HX; Hu MN; Yu X; Xu H
    Yao Xue Xue Bao; 2015 Sep; 50(9):1174-9. PubMed ID: 26757556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC-LIF: liposomal carrier for enhanced drug delivery.
    Ho JA; Fan NC; Jou AF; Wu LC; Sun TP
    Talanta; 2012 Sep; 99():683-8. PubMed ID: 22967611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.